Start With These Four Facts
The biggest questions first, before the detail.
There Is No Separate Postpartum Approval
No GLP-1 label has an approval written for the months after birth. Wegovy®, Zepbound® and Foundayo™ are approved for weight reduction in adults who meet the criteria on their labels.
Breastfeeding Statements Differ by Medicine
The labels for Wegovy® tablets, Rybelsus®, Ozempic® tablets and Foundayo™ say breastfeeding is not recommended during treatment. The injection labels say the benefits of breastfeeding should be considered along with the parent's need for the medicine and any possible effects on the breastfed baby.
Future Pregnancy Needs a Plan
The semaglutide labels say to stop at least 2 months before a planned pregnancy. The tirzepatide and Foundayo™ labels have specific notes about birth control pills.
Timing Is Personal
Recovery, feeding and sleep all shape when, or whether, a medicine makes sense. That timing is a decision to make with your prescriber.
Breastfeeding: What Each Label Says
Each label is quoted separately, so different statements are never blended into one claim. The Wegovy® and Ozempic® injection labels and the Mounjaro® and Zepbound® labels share one sentence, in full:
"The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for [the medicine] and any potential adverse effects on the breastfed infant from [the medicine] or from the underlying maternal condition."
| Medicine | Form | What the label says about breastfeeding | Label revised |
|---|---|---|---|
| Wegovy® tablets | Daily tablet | Breastfeeding is not recommended during treatment, because an absorption ingredient called SNAC is found in breast milk and may build up in infants. | 06/2026 |
| Wegovy® and Ozempic® injections | Weekly injection | No data on whether injected semaglutide is in breast milk or how it affects a breastfed baby or milk supply. The benefits of breastfeeding should be considered along with the parent's need for the medicine and any possible effects on the breastfed baby. | 06/2026 (Wegovy®), 05/2026 (Ozempic®) |
| Rybelsus® and Ozempic® tablets | Daily tablet | Breastfeeding is not recommended during treatment, because an absorption ingredient called SNAC is found in breast milk and may build up in infants. | 01/2026 |
| Mounjaro® and Zepbound® | Weekly injection | In a single-dose study of 11 breastfeeding adults, tirzepatide in breast milk was undetectable or low. No data on effects on the breastfed infant or on milk production. The benefits of breastfeeding should be considered along with the parent's need for the medicine and any possible effects on the breastfed baby. | 08/2026 |
| Foundayo™ | Daily tablet | No data on whether it passes into human milk; it was found in the milk of lactating rats. Foundayo™ is not recommended for nursing women. | 07/2026 |
Wegovy® Tablets
The Wegovy® label advises that breastfeeding is not recommended during treatment with Wegovy® tablets. It explains this is because an ingredient in the tablet that helps absorption, called SNAC, is found in breast milk and may build up in infants.
Wegovy® and Ozempic® Injections
The semaglutide injection labels say there are no data on whether injected semaglutide is in breast milk or how it affects a breastfed baby or milk supply. They say the benefits of breastfeeding should be considered along with the parent's need for the medicine and any possible effects on the breastfed baby.
Mounjaro® and Zepbound®
In a single-dose study of 11 breastfeeding adults described on the tirzepatide labels, tirzepatide in breast milk was undetectable or low. The labels add that there are no data on effects on the breastfed infant or on milk production. They say the benefits of breastfeeding should be considered along with the parent's need for the medicine and any possible effects on the breastfed baby.
Rybelsus® and Ozempic® Tablets
The label says breastfeeding is not recommended during treatment with these tablets, because an absorption ingredient called SNAC is found in breast milk and may build up in infants. This statement is in section 8.2 of the Rybelsus® and Ozempic® tablets label, revised January 2026.
Foundayo™
The label says there are no data on whether Foundayo™ passes into human milk, that it was found in the milk of lactating rats, and that Foundayo™ is not recommended for nursing women. This statement is in section 8.2 of the Foundayo™ label, revised July 2026.
Weighing It With Your Prescriber
The labels for Wegovy® tablets, Rybelsus®, Ozempic® tablets and Foundayo™ say breastfeeding is not recommended during treatment. Bring your feeding plans, and your baby's pediatrician's input, to the conversation with your prescriber.
Planning for Another Pregnancy
A future pregnancy changes the plan, and the labels are specific about it.
Semaglutide's Two-Month Note
The Wegovy®, Ozempic® and Rybelsus® labels say to stop at least 2 months before a planned pregnancy because semaglutide takes a long time to leave the body. Bring this up early if another baby is in your plans.
Tirzepatide and Birth Control Pills
The Mounjaro® and Zepbound® labels say tirzepatide may make oral hormonal birth control less effective. They advise a non-oral method, or adding a barrier method, for 4 weeks after starting and 4 weeks after each dose increase.
Foundayo™ and Birth Control
The Foundayo™ label asks women who could become pregnant to use effective birth control during treatment. It also advises switching from birth control pills to a non-oral method, or adding a barrier method, for 30 days after starting and for 30 days after each dose increase.
If You Become Pregnant Again
The Zepbound® label says to stop once a pregnancy is recognized, and the Wegovy® label says to stop it in pregnant patients using it for weight reduction or heart-risk reduction. The Foundayo™ label also says to stop once a pregnancy is recognized. Contact your prescriber as soon as you know.
Pregnancy Registries
Both the Wegovy® and Zepbound® labels list a pregnancy exposure registry for people who become pregnant while taking them. Your prescriber can help you decide whether to take part.
- Wegovy®: Novo Nordisk at 1-877-390-2760 or www.wegovypregnancyregistry.com
- Zepbound®: 1-844-524-0039 or MILEregistry@thermofisher.com
- Foundayo™: the label says a registry is planned and asks pregnant patients to contact Eli Lilly at 1-800-LillyRx (1-800-545-5979)
How Soon After Birth? Questions for Your Prescriber
The honest answer is that the labels do not say. These questions keep the decision with your prescriber. This is not medical advice.
The Labels Do Not Set a Start Date
None of these labels give a number of weeks after birth before starting. Your prescriber will look at your recovery, feeding and health history.
Ask How Feeding Changes the Choice
Ask whether breastfeeding or pumping changes which medicine, if any, makes sense. Tell your prescriber if you are breastfeeding or pumping.
Ask About Birth Control and Spacing
Ask which birth control method works with the medicine and how a future pregnancy would change the plan. Write the answers down while they are fresh.
Ask What to Report
Ask which symptoms mean a call right away and which can wait for the next visit. Severe stomach pain that will not go away and signs of an allergic reaction are among the label warnings that need prompt care. Every GLP-1 label on this page carries a boxed warning about thyroid C-cell tumors seen in rodents, and none of these medicines should be used by anyone with a personal or family history of medullary thyroid carcinoma or MEN 2.
What to Track in the Early Months
With a newborn, tracking has to be quick and forgiving. Four things are worth a few seconds a day.
Sleep in Pieces
Broken sleep affects energy, mood and appetite, so it is worth a quick note each day. Even a rough score helps explain a hard week later.
Water and Protein on Rushed Days
Meals often get skipped or eaten one-handed in the early months. Keeping an eye on water and protein shows the gaps before they become a pattern.
Weight as a Slow Trend
Weight after birth shifts for many reasons, including fluid and feeding. A trend over weeks is far kinder, and more useful, than a daily number.
Mood Check-Ins
A daily mood note takes seconds and can show a change you might not notice day to day. If low mood or worry lasts, tell your healthcare provider.
For support, call or text the National Maternal Mental Health Hotline at 1-833-852-6262 (1-833-TLC-MAMA), free and open 24/7, or contact Postpartum Support International's HelpLine at 1-800-944-4773 (postpartum.net). If you are in crisis or thinking about harming yourself, call or text 988, or call 911.
From the makers of this guide
Pep AI When Your Hands Are Full
New parents need logging that takes seconds. Pep AI is a tracking app, not a medical device, and it never tells you whether or when to take a medicine.
- 01
Quick Dose Logging
Pep AI logs each GLP-1 shot or pill on the schedule your prescriber set. On iPhone, you can log a scheduled dose in one tap from the Lock Screen, the large Next Dose widget or the Apple Watch app. A body map marks your last injection site, and for weekly shots and Foundayo™ an estimated medication-level chart shows how levels may change between doses.
- 02
Reminders That Fit a Newborn Schedule
Shot-day reminders appear on your Lock Screen, and on iPhone, widgets and the Apple Watch app keep the next dose in view. Nothing depends on remembering at 3 a.m.
- 03
Log a Meal From a Photo
Snap a photo, scan a barcode, search for a food, or tell Pep Bot, the in-app assistant, what you ate by typing or speaking, and Pep AI estimates protein, fiber and other nutrients. Water goals sit beside them so both are easy to check.
- 04
Symptoms, Sleep and Mood Together
Pep AI lets you rate side effects such as nausea, headache and fatigue for severity each day, from a built-in list of GLP-1 symptoms grouped by body area, plus your own. A quick daily check-in adds energy, mood and sleep.
Take Your Notes to the Appointment
A record is most useful when it reaches your prescriber.
A Report Ready Before the Visit
Pep AI turns your full history, including your doses and weight, into a PDF report. Send it ahead or show it on your phone, which saves time in a short appointment.
Food When Time Is Short
For quick ways to log meals with protein and fiber first, see the GLP-1 food tracker. A shopping list built for smaller appetites is in the GLP-1 grocery list.
Side Effects Explained
Common and serious side effects from the labels are covered in GLP-1 side effects. To rate them for severity each day, see the side effects tracker.
Key takeaways
- No GLP-1 label sets a postpartum start date; when, or whether, to start is a decision for you and your prescriber.
- The Wegovy® tablets, Rybelsus®, Ozempic® tablets and Foundayo™ labels say breastfeeding is not recommended during treatment.
- The injection labels say the benefits of breastfeeding should be considered along with the parent's need for the medicine and any possible effects on the breastfed baby.
- The semaglutide labels say to stop at least 2 months before a planned pregnancy; the tirzepatide and Foundayo™ labels have birth control pill notes.
- Every label carries a boxed warning about thyroid C-cell tumors. If low mood or worry lasts, the National Maternal Mental Health Hotline is 1-833-852-6262.
Logging that fits around a newborn.
Pep AI logs doses, symptoms with severity, meals, water, sleep and mood, and makes a PDF of your doses, injection sites and weight. Free to try on iPhone and Android.
Frequently asked questions
Keep reading
Sources
- Wegovy® (semaglutide) injection and tablets prescribing information and Medication Guide, Novo Nordisk / FDA (revised 06/2026)
- Zepbound® (tirzepatide) prescribing information and Medication Guide, Eli Lilly / FDA (revised 08/2026)
- Mounjaro® (tirzepatide) prescribing information, Eli Lilly / FDA (revised 08/2026)
- Ozempic® (semaglutide) injection prescribing information and Medication Guide, Novo Nordisk / FDA (revised 05/2026)
- Rybelsus® and Ozempic® tablets (semaglutide) prescribing information, Novo Nordisk / FDA (revised 01/2026)
- Foundayo™ (orforglipron) prescribing information, Eli Lilly / FDA (revised 07/2026)
This guide is general information based on FDA prescribing information and published research. No GLP-1 label sets a postpartum start date, and breastfeeding statements differ by medicine. Pep AI does not recommend any medicine, any dose, or any use that is not on a medicine's label. It is not medical advice and does not replace your prescriber, gynecologist or pharmacist, and Pep AI is not affiliated with Novo Nordisk or Eli Lilly. If a symptom is severe, getting worse, or worrying you, contact your healthcare provider. In an emergency, call 911.
Published by the Pep AI team · Updated November 2026